Doctor Filipe Moura

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

Membership: ESC Professional Member

Follow

Contributor content

Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: A patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials

Presentation

Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: A patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials

ESC 365 is supported by

novartis

Explore sponsored resources